Advancing Precision Medicine through Menin Inhibitors in Acute Leukemia

Acute myeloid leukemia (AML) is a challenging blood cancer to treat, especially in older adults. Even with advances in understanding its genetic and molecular features, many patients still face poor long-term survival. This makes the development of safer, more effective therapies a high priority.

I have been involved in the clinical development of menin inhibitors which are oral drugs that can “reprogram” leukemia cells, helping them return to a more normal pattern of gene activity. One of these drugs, revumenib, was recently approved by the FDA for patients with resistant leukemia who have specific genetic changes in the KMT2A or NPM1 genes. Together, these mutations account for up to a third of AML cases and a substantial fraction of leukemia in children. However, other smaller subgroups of patients may also benefit from this therapy though current clinical testing cannot accurately identify them.

While menin inhibitors are very promising, resistance can occur when they are used alone. Laboratory studies suggest that combining them with other treatments may make responses stronger and longer lasting. My research focuses on using advanced lab technologies to understand who responds best to these therapies, why some leukemia cells respond while others resist treatment, and to detect leukemia at extremely low levels. By combining these laboratory insights with clinical trials, I aim to design the most effective treatment strategies and translate these discoveries directly to patient care.